Anne Sofie Brems-Eskildsen
About
In The Last Decade
Anne Sofie Brems-Eskildsen
9 papers receiving 335 citations
Peers
Comparison fields: 5 of 47
- Molecular Biology 222
- Surgery 93
- Cancer Research 92
- Pulmonary and Respiratory Medicine 71
- Oncology 67
Countries citing papers authored by Anne Sofie Brems-Eskildsen
This map shows the geographic impact of Anne Sofie Brems-Eskildsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Sofie Brems-Eskildsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Sofie Brems-Eskildsen more than expected).
Fields of papers citing papers by Anne Sofie Brems-Eskildsen
This network shows the impact of papers produced by Anne Sofie Brems-Eskildsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Sofie Brems-Eskildsen. The network helps show where Anne Sofie Brems-Eskildsen may publish in the future.
Co-authorship network of co-authors of Anne Sofie Brems-Eskildsen
This figure shows the co-authorship network connecting the top 25 collaborators of Anne Sofie Brems-Eskildsen. A scholar is included among the top collaborators of Anne Sofie Brems-Eskildsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Sofie Brems-Eskildsen. Anne Sofie Brems-Eskildsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 9 | |
| 2 | 6 | |
| 3 | 3 | |
| 4 | Is metronomic chemotherapy less toxic than conventional chemotherapy in the randomized phase 2 XeNa trial combining navelbine oral and Xeloda for HER2 negative breast cancer patients | 0 |
| 5 | Uniform Combretastatin-induced Effect on Monocytes and Neutrophils in Peripheral Blood but Not in Tumors. | 2 |
| 6 | 7 | |
| 7 | 1 | |
| 8 | 76 | |
| 9 | 56 | |
| 10 | 181 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.